ADAG - Adagene Inc
3.66
-0.130 -3.552%
Share volume: 30,863
Last Updated: 05-12-2026
Pharmaceutical Products/Pharmaceutical Preparations:
0.10%
PREVIOUS CLOSE
CHG
CHG%
$3.79
-0.13
-0.03%
Fundamental analysis
8%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
20%
Performance
5 Days
-0.81%
1 Month
-4.69%
3 Months
12.62%
6 Months
103.33%
1 Year
112.79%
2 Year
64.13%
Key data
Stock price
$3.66
DAY RANGE
$3.56 - $3.70
52 WEEK RANGE
$1.30 - $4.75
52 WEEK CHANGE
$110.90
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-24-2025
Company detail
CEO: Pei Z. Luo
Region: US
Website: adagene.com
Employees: 260
IPO year: 2021
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: adagene.com
Employees: 260
IPO year: 2021
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 mAb that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma.
Recent news